## American College of Radiology
### ACR Appropriateness Criteria®

**Post-Treatment Surveillance of Bladder Cancer**

**Variant 1:** Nonmuscle invasive bladder cancer (NMIBC), no symptoms or risk factors. Post-treatment surveillance.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Appropriateness Category</th>
<th>SOE</th>
<th>Adults RRL</th>
<th>Peds RRL</th>
<th>Rating</th>
<th>Median</th>
<th>Final Tabulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI abdomen and pelvis without and with IV contrast</td>
<td>Usually not appropriate</td>
<td>Strong</td>
<td>0 0 mSv</td>
<td>0 0 mSv [ped]</td>
<td>3</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Radiography intravenous urography</td>
<td>Usually not appropriate</td>
<td>Expert Consensus</td>
<td>1-10 mSv</td>
<td>0.3-3 mSv [ped]</td>
<td>3</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>CT abdomen and pelvis without and with IV contrast</td>
<td>Usually not appropriate</td>
<td>Limited</td>
<td>10-30 mSv</td>
<td>10-30 mSv [ped]</td>
<td>3</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Radiography chest</td>
<td>Usually not appropriate</td>
<td>Expert Consensus</td>
<td>&lt;0.1 mSv</td>
<td>&lt;0.03 mSv [ped]</td>
<td>2</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>US pelvis (bladder)</td>
<td>Usually not appropriate</td>
<td>Strong</td>
<td>0 0 mSv</td>
<td>0 0 mSv [ped]</td>
<td>1</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
</tbody>
</table>

**References**

<table>
<thead>
<tr>
<th>Study Quality</th>
<th>23 (10992362)</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>24 (10367843)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>29 (24072383)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>28 (26760195)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>30 (20152273)</td>
<td>3</td>
</tr>
</tbody>
</table>

**Study Quality**

<table>
<thead>
<tr>
<th>Study Quality</th>
<th>27 (23680310)</th>
<th>3</th>
</tr>
</thead>
</table>

**Notes:**
- RRL: Relative Risk Level
- SOE: Strength of Evidence
- Median: Median Rating
- Final Tabulations: Frequency of Rating
- [ped]: Pediatric information provided in square brackets.
<table>
<thead>
<tr>
<th>References</th>
<th>Study Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 (21655537)</td>
<td>2</td>
</tr>
<tr>
<td>26 (18096730)</td>
<td>2</td>
</tr>
</tbody>
</table>

**MRI abdomen and pelvis without IV contrast**

<table>
<thead>
<tr>
<th>References</th>
<th>Study Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 (10367843)</td>
<td>4</td>
</tr>
<tr>
<td>23 (10992362)</td>
<td>3</td>
</tr>
<tr>
<td>30 (20152273)</td>
<td>3</td>
</tr>
<tr>
<td>29 (24072383)</td>
<td>2</td>
</tr>
<tr>
<td>28 (26760195)</td>
<td>2</td>
</tr>
</tbody>
</table>

**CT chest without and with IV contrast**

<table>
<thead>
<tr>
<th>References</th>
<th>Study Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 (23680310)</td>
<td>3</td>
</tr>
</tbody>
</table>

**CT chest without IV contrast**

<table>
<thead>
<tr>
<th>References</th>
<th>Study Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 (23680310)</td>
<td>3</td>
</tr>
</tbody>
</table>

**CT chest with IV contrast**

<table>
<thead>
<tr>
<th>References</th>
<th>Study Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 (23680310)</td>
<td>3</td>
</tr>
</tbody>
</table>

**CT abdomen and pelvis without IV contrast**

<table>
<thead>
<tr>
<th>References</th>
<th>Study Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 (23680310)</td>
<td>3</td>
</tr>
</tbody>
</table>

**CT abdomen and pelvis with IV contrast**

<table>
<thead>
<tr>
<th>References</th>
<th>Study Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 (23680310)</td>
<td>3</td>
</tr>
</tbody>
</table>

**FDG-PET/CT skull base to mid-thigh**

<table>
<thead>
<tr>
<th>References</th>
<th>Study Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 (23680310)</td>
<td>3</td>
</tr>
</tbody>
</table>
Nonmuscle invasive bladder cancer (NMIBC), with symptoms or risk factors. Post-treatment surveillance.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Appropriateness Category</th>
<th>SOE</th>
<th>Adults RRL</th>
<th>Peds RRL</th>
<th>Rating</th>
<th>Median</th>
<th>Final Tabulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT abdomen and pelvis without and with IV contrast</td>
<td>Usually appropriate</td>
<td>Limited</td>
<td>1-30 mSv</td>
<td>10-30 mSv [ped]</td>
<td>8</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>References</td>
<td>Study Quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35 (25341140)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36 (18796677)</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI abdomen and pelvis without and with IV contrast</td>
<td>May be appropriate</td>
<td>Strong</td>
<td>0 mSv</td>
<td>0 mSv [ped]</td>
<td>6</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>References</td>
<td>Study Quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28 (26760195)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29 (24072383)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37 (19332849)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38 (19247665)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39 (20171676)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiography chest</td>
<td>May be appropriate</td>
<td>Expert Consensus</td>
<td>&lt;0.1 mSv</td>
<td>&lt;0.03 mSv [ped]</td>
<td>5</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>MRI abdomen and pelvis without IV contrast</td>
<td>Usually not appropriate</td>
<td>Strong</td>
<td>0 mSv</td>
<td>0 mSv [ped]</td>
<td>3</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>References</td>
<td>Study Quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28 (26760195)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29 (24072383)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37 (19332849)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38 (19247665)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39 (20171676)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedure</td>
<td>Appropriateness</td>
<td>Expert Consensus</td>
<td>Dose (mSv)</td>
<td>Study Quality</td>
<td>References</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-----------------</td>
<td>------------------</td>
<td>------------</td>
<td>--------------</td>
<td>------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiography intravenous urography</td>
<td>Usually not appropriate</td>
<td>Expert Consensus</td>
<td>☢☢☢ 1-10 mSv</td>
<td>3</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>CT abdomen and pelvis with IV contrast</td>
<td>Usually not appropriate</td>
<td>Limited</td>
<td>☢☢☢ 1-10 mSv</td>
<td>3</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>References</td>
<td>Study Quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>35 (25341140)</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36 (18796677)</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDG-PET/CT skull base to mid-thigh</td>
<td>Usually not appropriate</td>
<td>Expert Consensus</td>
<td>☢☢☢ 10-30 mSv</td>
<td>3</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>References</td>
<td>Study Quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>25 (21655537)</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>26 (18096730)</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US pelvis (bladder)</td>
<td>Usually not appropriate</td>
<td>Strong</td>
<td>☢☢☢ 0 mSv</td>
<td>1</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>References</td>
<td>Study Quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>35 (25341140)</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36 (18796677)</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT chest without and with IV contrast</td>
<td>Usually not appropriate</td>
<td>Expert Consensus</td>
<td>☢☢☢ 1-10 mSv</td>
<td>1</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>References</td>
<td>Study Quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>35 (25341140)</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36 (18796677)</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT chest without IV contrast</td>
<td>Usually not appropriate</td>
<td>Expert Consensus</td>
<td>☢☢☢ 1-10 mSv</td>
<td>1</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>References</td>
<td>Study Quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>35 (25341140)</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36 (18796677)</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT chest with IV contrast</td>
<td>Usually not appropriate</td>
<td>Expert Consensus</td>
<td>☢☢☢ 1-10 mSv</td>
<td>1</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>References</td>
<td>Study Quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>35 (25341140)</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36 (18796677)</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT abdomen and pelvis without IV contrast</td>
<td>Usually not appropriate</td>
<td>Limited</td>
<td>☢☢☢ 1-10 mSv</td>
<td>1</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>References</td>
<td>Study Quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>35 (25341140)</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36 (18796677)</td>
<td>3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Variant 3: Muscle-invasive bladder cancer (MIBC) with or without cystectomy. Post-treatment surveillance.
<table>
<thead>
<tr>
<th>Procedure</th>
<th>Appropriateness Category</th>
<th>SOE</th>
<th>Adults RRL</th>
<th>Peds RRL</th>
<th>Rating</th>
<th>Median</th>
<th>Final Tabulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiography chest</td>
<td>Usually appropriate</td>
<td>Expert Consensus</td>
<td>☢️ &lt;0.1 mSv</td>
<td>☢️ &lt;0.03 mSv [ped]</td>
<td>9</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>Fluoroscopy abdomen loopogram</td>
<td>Usually appropriate</td>
<td>Expert Consensus</td>
<td>☢☢☢ 1-10 mSv</td>
<td>☢☢☢ 1-10 mSv [ped]</td>
<td>8</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>CT abdomen and pelvis without and with IV contrast</td>
<td>Usually appropriate</td>
<td>Limited</td>
<td>☢☢☢☢ 10-30 mSv</td>
<td>☢☢☢☢ 10-30 mSv [ped]</td>
<td>8</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>MRI abdomen and pelvis without and with IV contrast</td>
<td>Usually appropriate</td>
<td>Limited</td>
<td>O 0 mSv</td>
<td>O 0 mSv [ped]</td>
<td>7</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>CT abdomen and pelvis with IV contrast</td>
<td>Usually appropriate</td>
<td>Limited</td>
<td>☢☢☢ 1-10 mSv</td>
<td>☢☢☢ 3-10 mSv [ped]</td>
<td>7</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td>CT chest with IV contrast</td>
<td>May be appropriate</td>
<td>Expert Consensus</td>
<td>☢☢☢ 1-10 mSv</td>
<td>☢☢☢ 3-10 mSv [ped]</td>
<td>6</td>
<td>6</td>
<td>0 0 0 2 5 7 1 1 0</td>
</tr>
<tr>
<td>MRI abdomen and pelvis without IV contrast</td>
<td>May be appropriate</td>
<td>Limited</td>
<td>O 0 mSv</td>
<td>O 0 mSv [ped]</td>
<td>5</td>
<td>n/a</td>
<td>0 0 0 0 0 0 0 0 0</td>
</tr>
</tbody>
</table>

References

Study Quality

<table>
<thead>
<tr>
<th>References</th>
<th>Study Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>35 (25341140)</td>
<td>1</td>
</tr>
<tr>
<td>39 (20171676)</td>
<td>2</td>
</tr>
<tr>
<td>50 (19396568)</td>
<td>3</td>
</tr>
<tr>
<td>51 (19914691)</td>
<td>3</td>
</tr>
<tr>
<td>Procedure</td>
<td>Appropriateness</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>CT chest without IV contrast</td>
<td>May be appropriate</td>
</tr>
<tr>
<td>FDG-PET/CT skull base to mid-thigh</td>
<td>May be appropriate</td>
</tr>
<tr>
<td>US pelvis (bladder)</td>
<td>Usually not appropriate</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiography intravenous urography</td>
<td>Usually not appropriate</td>
</tr>
<tr>
<td>CT abdomen and pelvis without IV contrast</td>
<td>Usually not appropriate</td>
</tr>
<tr>
<td>CT chest without and with IV contrast</td>
<td>Usually not appropriate</td>
</tr>
</tbody>
</table>
Appendix Key
A more complete discussion of the items presented below can be found by accessing the supporting documents at the designated hyperlinks.

**Appropriateness Category**: The panel's recommendation for a procedure based on the assessment of the risks and benefits of performing the procedure for the specified clinical scenario.

**SOE**: Strength of Evidence. The assessment of the amount and quality of evidence found in the peer reviewed medical literature for an appropriateness recommendation.

- **References**: The citation number and PMID for the reference(s) associated with the recommendation.
- **Study Quality**: The assessment of the quality of an individual reference based on the number of study quality elements described in the reference.

**RRL**: Relative Radiation Level. A population based assessment of the amount of radiation a typical patient may be exposed to during the specified procedure.

**Rating**: The final rating (1-9 scale) for the procedure as determined by the panel during rating rounds.

**Median**: The median rating (1-9 scale) for the procedure as determined by the panel during rating rounds.

**Final tabulations**: A histogram showing the number of panel members who rated the procedure as noted in the column heading (ie, 1, 2, 3, etc.).

Additional supporting documents about the AC methodology and processes can be found at [www.acr.org/ac](http://www.acr.org/ac).